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Abstract
Objective: The nicotinamide-nucleotide adenylyltransferase protein Nmnat1 is
a potent inhibitor of axonal degeneration in models of acute axonal injury.
Hyperphosphorylation and aggregation of the microtubule-associated protein
Tau are associated with neurodegeneration in Alzheimer’s Disease and other
disorders. Previous studies have demonstrated that other Nmnat isoforms can
act both as axonoprotective agents and have protein chaperone function, exert-
ing protective effects in drosophila and mouse models of tauopathy. Nmnat1
targeted to the cytoplasm (cytNmnat1) is neuroprotective in a mouse model of
neonatal hypoxia-ischemia, but the effect of cytNmnat1 on tauopathy remains
unknown. Methods: We examined the impact of overexpression of cytNmnat1
on tau pathology, neurodegeneration, and brain functional connectivity in the
P301S mouse model of chronic tauopathy. Results: Overexpression of
cytNmnat1 preserved cortical neuron functional connectivity in P301S mice
in vivo. However, whereas Nmnat1 overexpression decreased the accumulation
of detergent-insoluble tau aggregates in the cerebral cortex, it exerted no effect
on immunohistochemical evidence of pathologic tau phosphorylation and mis-
folding, hippocampal atrophy, or inflammatory markers in P301S mice. Inter-
pretation: Our results demonstrate that cytNmnat1 partially preserves neuronal
function and decreases biochemically insoluble tau in a mouse model of
chronic tauopathy without preventing tau phosphorylation, formation of sol-
uble aggregates, or tau-induced inflammation and atrophy. Nmnat1 might thus
represent a therapeutic target for tauopathies.
Introduction
The family of nicotinamide-nucleotide adenylyltransferase
(Nmnat) proteins has been broadly studied for their
potent axonal protective effects.1–3 These enzymes catalyze
the conversion of nicotinamide mononucleotide to NAD+
in the final step of the NAD+ salvage pathway. Nmnat
enzymes thus contribute to neuronal health via mainte-
nance of cellular NAD+ levels, although they also appear
to exert NAD+-independent cytoprotective effects.2,4,5
There are three mammalian Nmnat isoforms: a nuclear
form (Nmnat1), a cytoplasmic form (Nmnat2), and a
mitochondrial form (Nmnat3). Overexpression of each of
these isoforms can prevent axonal degeneration in neu-
rons.3,6,7 Targeting of Nmnat1 to the cytoplasm has been
shown to exert very potent axonoprotective effects, and
to suppress neuronal death in the brain of newborn mice
caused by hypoxia-ischemia.3,8 Thus, modulation of
Nmnat function is an attractive potential target for the
treatment of peripheral nerve injuries, and has been pos-
tulated as a possible therapeutic target for the treatment
of central nervous system degenerative diseases.
The microtubule-associated protein tau has long been
implicated as a major contributor to several age-related
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neurodegenerative diseases, including Alzheimer’s Disease
(AD) and Frontotemporal dementia.9 Intraneuronal
aggregates of hyperphosphorylated tau, termed neurofib-
rillary tangles, are observed in AD, and correlate closely
with neurodegeneration. Elevated levels of tau and phos-
pho-tau are also observed in the cerebrospinal fluid of
AD patients and predict the subsequent onset of demen-
tia.10,11 Mutations in the MAPT gene, which encodes tau
protein, cause an adult-onset neurodegenerative disease
characterized by frontotemporal dementia and Parkinson-
ism.12 Transgenic mice expressing these mutant human
tau genes exhibit progressive accumulation of hyperphos-
phorylated tau aggregates, as well as neuroinflammation
and neurodegeneration.13,14 Thus, strategies which miti-
gate tau accumulation or toxicity have clear implications
for the treatment of AD and other neurodegenerative dis-
eases.
Several studies have described a potential relationship
between Nmnat enzymes and tau pathology. In droso-
phila models of tauopathy, dNmnat overexpression miti-
gates tau pathology, perhaps by directly targeting
phospho-tau species to the proteasome.15 In mammalian
systems, overexpression of Nmnat2 mitigates tau phos-
phorylation in HEK293 cells in a PP2a-dependent man-
ner.16 Likewise, Nmnat2 overexpression in a mouse
model of accelerated tauopathy (rTg4510) prevented cor-
tical neuron loss and reduced the accumulation of phos-
phorylated tau, although detailed immunohistochemical
examination of tau pathology was not performed.17 In
that study, viral overexpression of a nontargeted form of
Nmnat1 also mitigated cortical thinning in rTg4510 mice,
although the effect on tau aggregation was not assessed.
Nmnat1 exerts profound axonal protection in models of
axonal degeneration, particularly when it is expressed
specifically in the cytoplasm.3 Importantly, cytoplasmic-
targeted Nmnat1 (cytNmnat1) also prevents neurodegen-
eration in a mouse model of neonatal hypoxic-ischemic
injury, and protects cortical neuronal cultures form
NMDA toxicity,8 suggesting that this form of Nmnat
might possess neurprotective attributes which go beyond
axonal protection. Thus, we sought to examine the
impact of cytoplasmic-targeted Nmnat1 on tau pathology
and brain functional connectivity in the transgenic P301S
tau mouse model of chronic tauopathy.
Methods
Animals
P301S mouse breeders (PS19 strain) on a mixed B6C3
background were generously provided by the lab of Dr.
Virginia Lee.14 cytNmnat1 transgenic mice were generated
in the Milbrandt lab as previously described3 on a C57/B6
background. cytNmnat1 Tg mice were bred with P301S
mice, and only F1 generation mice (all on a mixed
genetic background) were used in the experiments. Only
female mice were included. All experiments were per-
formed in accordance with protocols approved by the
Washington Univ. Department of Comparative Medicine.
Optical imaging of functional connectivity
Optical intrinsic signal imaging of resting state functional
connectivity (fcOIS) in mice was performed as previously
described.18,19 Briefly, mice were anesthetized with i.p.
Ketamine/Xylazine mixture (86.9 mg/kg Ketamine,
13.4 mg/kg Xylazine). Once induced, each animal was
placed on a heating pad maintained at 37°C (mTCII, Cell
Microcontrols) and its head secured in a stereotactic
frame. The scalp fur was shaved, and a midline incision
was made along the top of the head and the scalp was
reflected, exposing approximately 1 cm2 of the skull. The
skull was kept moist with an application of mineral oil.
Sequential illumination of the skull surface was provided
at four wavelengths by a ring of light-emitting diodes
placed approximately 10 cm above the mouse’s head.
Images were captured using a cooled, frame-transfer
EMCCD camera (iXon 897, Andor Technologies) which
was time synchronized and controlled via computer using
custom-written software (MATLAB, Mathworks). Images
were acquired at a frame rate of 120 Hz, and seven to
nine 5-min imaging sessions were performed per mouse.
Correlation coefficients were generated between regions of
interest (ROIs), which were then subjected to Fisher
transformation and normalized to the wt mean. The ret-
rosplenial cortex ROI was chosen a priori in order to
minimize the statistical effects of multiple comparisons
across several ROIs, as the retrosplenial cortex has previ-
ously been shown to be susceptible to loss of functional
connectivity in the setting of aging or neuronal injury.19,20
All analysis of fcOIS imaging data and correlation coeffi-
cients was carried out by an investigator who was blinded
to genotype.
Quantitative PCR
Brain tissue was homogenized directly in Trizol (Invitro-
gen) using a motorized grinder. Chloroform (1:5) was
added, samples were agitated then centrifuged at 13,000g
for 15 min at 4 degrees, and the chloroform layer was
removed, diluted 1:1 in 70% ethanol, then purified using
RNeasy columns and reagents (Qiagen, Valencia, CA).
Reverse transcription was performed using high-capacity
RNA-cDNA kit (Applied Biosystems (ABI), Carlsbad, CA)
with 1 ug RNA per 20 uL reaction. Real-time qPCR was
performed using ABI Taqman primers and reagents on an
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ABI Prizm 7500 thermocycler according to manufacturer’s
instructions. All mRNA measurements were normalized
to beta-actin (Actb) mRNA levels. Taqman primer sets
were obtained from Life Technologies using their propri-
etary sequences.
Immunohistochemistry
Mice were anesthetized via i.p. injection of pentobarbital,
then transcardiac perfusion was performed for 3 min with
ice-cold Dulbecco’s modified PBS (dPBS) containing 3 g/
L heparin. One hemisphere was dissected on ice then
flash frozen in liquid nitrogen for biochemical analyses,
whereas the other hemisphere was fixed in 4%
paraformaldehyde for 24 h (4°C), then cryoprotected with
30% sucrose in PBS (4°C) for 48 h, then frozen in pow-
dered dry ice, and cut on a freezing sliding microtome.
Serial coronal sections (50 lm thick) were collected from
the prefrontal cortex to caudal hippocampus. Sections
(each separated by 300 mm) were placed in 12 well plates
in mesh inserts for staining. Sections were incubated in
0.3% hydrogen peroxide for 10 min, washed in tris-buf-
fered saline (TBS), blocked for 30 min TBS-containing
3% goat and 0.25% triton X-100, then incubated over-
night in TBS + 0.25% triton X-100 with 1% goat serum
containing rabbit AT8 (Thermo Scientific, 1:500) or rab-
bit MC1 (1:1000) primary antibodies at 4°C. Sections
were washed then incubated in TBS-containing biotiny-
lated goat anti-rabbit secondary antibody (1:1000) for 1 h
at room temperature, then washed again in TBS. Sections
were then incubated in TBS-containing 1:400 dilution of
streptavidin-conjugated HRP (VECTASTAIN ABC Elite,
Vector Labs, Burlingame, CA). Following thorough
washes in TBS, sections were incubated with diaminoben-
zidine substrate with hydrogen peroxide and nickel chlo-
ride for 8 min. Sections were mounted on glass slides and
dried overnight, then subjected to serial dehydration and
coverslipping with Cytoseal mounting media. For volume
measurement, serial sections 300 lm apart were mounted
on gelatin-coated slides and dried overnight, then sub-
jected to cresyl violet staining as previously described.20
Stained sections were imaged with a NanoZoomer slide
scanner (Hamamatsu Photonics).
Image analysis was performed by an investigator
blinded to genotype, using a previously described
method.21 Images were obtained which included the
entire hippocampus. For MC1-stained sections, all sec-
tions were stained together in a single batch, so as to
eliminate batch effects. Using ImageJ software, images
were converted into grayscale. The lightest and darkest
stained sections were selected in a blinded manner, and a
threshold was set such that the lightest section was less
than 5% saturated, whereas the darkest section was less
than 90% saturated. The hippocampus boundaries were
then selected as the ROI, and this threshold was then
applied to all sections, and percent area of staining was
determined. For volumetric analysis, ROIs were drawn
around the hippocampus and the cortex immediately
above the hippocampus in a consistent manner on five
consecutive sections from each mouse, starting with the
section 300 lm after the first appearance of the anterior
hippocampus. The area of each ROI was determined then
multiplied by 300 lm (the depth between sequential sec-
tions) to yield a volume. Hippocampal and cortical vol-
umes were determined for each mouse, and normalized
as percent wt control.
Serial tau extraction and ELISA
Extraction and tau sandwich ELISA were performed as
described previously with minor modifications.21 The cor-
tex of each brain was homogenized in 30 lL/mg of RAB
buffer [100 mmol/L MES, 1 mmol/L EDTA, 0.5 mmol/L
MgSO4, 750 mmol/L NaCl, 20 mmol/L NaF, 1 mmol/L
Na3VO4, supplemented by protease inhibitor (Roche)
and phosphatase inhibitor (Roche)]. In brief, the samples
were centrifuged at 50,000g for 20 min at 4°C using an
Optima MAX-TL Ultracentrifuge (Beckman). The super-
natants were collected as RAB soluble fractions and pellets
were resuspended in RIPA buffer [150 mmol/L NaCl,
50 mmol/L Tris, 0.5% deoxycholic acid, 1% Triton X-
100, 0.5% SDS–25 mmol/L EDTA, pH 8.0, supplemented
by protease inhibitor (Roche) and phosphatase inhibitor
(Roche)], 30 lL/mg and centrifuged at 50,000g for
20 min at 4°C. The supernatants were collected as RIPA
soluble fractions. The pellets were further resuspended in
70% formic acid, 10 lL/mg, and centrifuged at 50,000g
for 20 min at 4°C. The supernatants were collected as
70% formic acid fractions. All fractions were stored in
80°C until analyzed.
To determine human tau levels, ELISA half 96 well
plates (Costar) were coated with Tau5 antibody (20 lg/
mL) in carbonate buffer pH 9.6 and incubated at 4°C,
overnight on a shaker. ELISA plates were washed five
times with PBS with a BioTek ELx405 plate washer and
blocked with 4% BSA in PBS for 1 h at 37°C. Plates were
then washed five times followed by incubating wells with
RAB, RIPA, or 70% Formic acid (FA) biochemically
extracted soluble brain tissue fractions diluted in sample
buffer (0.25% BSA in PBS, 300 nmol/L Tris pH 7.4 sup-
plemented by protease inhibitor) and incubated at 4°C.
FA fractions of 70% were neutralized by diluting 1:20
with 1M Tris pH 11 followed by diluting with sample
buffer. The next day, plates were washed eight times with
PBS followed by the addition of the biotinylated mouse
monoclonal anti-tau antibody HT7 antibody (0.3 lg/mL,
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Pierce) in 1% BSA in PBS for 1.5 h at 37°C. Plates were
then washed eight times in PBS followed by addition of
streptavidin-poly-horseradish peroxidase-40 (1:4000,
Fitzgerald), for 1.5 h, in the dark, at room temperature.
Plates were then washed eight times with PBS, developed
with Super Slow ELISA TMB (Sigma) and absorbance
read at 650 nm on BioTek Synergy two plate reader.
Recombinant human tau was used to create a standard in
each plate. The longest recombinant human (hTau40,
441aa) isoforms produced in the laboratory of Eva-Maria
Mandelkow were used as standards in the ELISA assays.
Results
We bred heterozygous P301S tau transgenic mice with
heterozygous cytNmnat1 transgenic mice to generate four
groups of female mice: wild type (wt), cytNmnat1 trans-
genic (Nmnat1), P301S tau transgenic (P301S), and
cytNmnat1-P301S double transgenic (DTg). Our Nmnat1
transgenic mice overexpress Nmnat1 which is targeted to
the cytoplasm and has been previously demonstrated to
exert optimal protection against axonal injury in vitro
and in vivo, as well as neuroprotection from neonatal
hypoxia-ischemia.3,8 We observed a 41-fold increase in
Nmnat1 mRNA in the cortex of our Nmnat1 transgenic
mice, and coexpression of P301S tau had no effect on the
degree of overexpression (Fig S1).
We next aged our four cohorts of female mice to
12 months of age. At this age severe tau pathology and
brain atrophy is evident in female P301S tau-expressing
mice. All surviving mice were then subjected to optical
intrinsic signal functional connectivity (fcOIS) imaging.
This technique involves optical imaging of blood flow in
the cerebral cortex of anesthetized mice and allows analy-
sis of correlative activity patterns in connected cortical
regions.18 Decreases in resting-state connectivity between
the bilateral retrosplenial cortices have been observed in
aged mice, as well as in several models of neurodegenera-
tion.19,20,22 We observed a significant decrease in retros-
plenial cortex functional connectivity in P301S mice as
compared to non–tau-expressing mice. Overexpression of
Nmnat1 partially rescued tau-induced fcOIS impairments,
suggesting that Nmnat1 can protect cortical neuronal
function from tau-mediated injury (Fig. 1).
Based on these observations, we examined tau-related
neuropathology in all four groups of mice. We observed
severe pathogenic tau phosphorylation and misfolding in
the hippocampi P310S and Nmnat1-P301S DTg mice, as
assessed using immunohistochemistry with the conforma-
tion-specific phospho-tau antibody MC123 (Fig. 2A). We
quantified the degree of MC1 immunoreactivity in the
retrosplenial cortex, as well as two hippocampal regions:
CA3, which exhibits relatively less tau pathology, and the
hilus of the dentate gyrus, which accumulates high levels
of pathogenic tau. Although there was considerable varia-
tion between mice, we unexpectedly found no significant
difference in the degree of hippocampal MC1 immunore-
activity between P310S and DTg mice in any of these
regions (Fig. 2B). There was no obvious difference in the
distribution or morphology of tau-reactive structure
between P301S and DTg mice, as both genotypes had
intracellular neuronal tau deposition and strong neuropil
staining. Similarly, staining of cortex and hippocampus
with the phosphorylation-specific tau antibody AT824 also
showed no substantial effect of Nmnat1 overexpression
on cortical or hippocampal phospho-tau pathology
(Fig. 2C and D).
We also observed atrophy of the hippocampus in
P301S tau-expressing mice, although we again found no
significant difference between P310S and DTg mice
(Fig. 3A). Cortical thickness was also not statistically dif-
ferent between P301S and DTg genotypes. Finally, we
examined the expression of a panel of transcripts related
to inflammation and oxidative stress via qPCR in the cor-
tex of all four groups of mice. Again, there was a signifi-
cant increase in mRNA for several inflammatory markers
in tau-expressing mice, including Tnfa and Gfap, but we
observed no significant effect of Nmnat1 overexpression
(Fig. 3B). We also quantified transcripts for redox
responsive genes, including Hmox1, which encodes the
Nrf2-regulated redox defense protein heme oxygenase 1,25
Figure 1. cytNmnat1 overexpression prevents Tau-induced loss of
functional connectivity. Retrosplenial cortex functional connectivity
was quantified in anesthetized mice using optical intrinsic signal
imaging (fcOIS). (A) Connectivity coefficient maps of the averaged
images from n = 5–7 mice/group are shown. The seed region is
denoted by the black dot. Correlated cerebral blood flow in the
contralateral retrosplenial cortex is shown in wt and cytNmnat1 mice,
but is diminished in P301S tau. Warmer colors indicate higher
connectivity. cytNmnat1/P301S tau double transgenic (DTg) mice
exhibit significant improvement in retrosplenial connectivity. (B)
Quantification of retrosplenial connectivity coefficient, present as %
of wt. *P < 0.05 by two-way T-test.
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and Pla2g3, which encodes a phospholipase A2 isoform
which has been previous demonstrated to be upregulated
in the setting of oxidative stress.26 Both transcripts
showed a nonsignificant trend toward upregulation in the
hippocampi of tau-expressing mice, with no significant
effect of Nmnat1 coexpression (Fig. S2). Thus, we con-
cluded that although Nmnat1 overexpression prevents
tau-induced loss of functional connectivity, it does not do
so by altering accumulation of phospho-tau, or by miti-
gating hippocampal atrophy, inflammation, or oxidative
stress.
Previous studies have suggested that Nmnat isoforms
possess chaperone function which can accelerate clearance
of aggregated species of tau and other proteins.15,27,28 We
next asked if Nmnat1 exerts any effect on levels of soluble
or insoluble (aggregated) tau species. We thus quantified
total tau levels by ELISA in cortical samples subjected to
serial extraction to look at salt-soluble, detergent-soluble,
and detergent-insoluble species.21 We observed no signifi-
cant difference in the amount of RAB (salt) or RIPA (de-
tergent)-soluble tau levels between P301S and DTg mice
(Fig. 4A and B). However, we found a small but statisti-
cally significant decrease in the amount of tau in the
detergent-insoluble (70% formic acid extracted) fraction
in DTg mice as compared to P301S mice (Fig. 4C). Thus,
Nmnat1 appears to modestly reduce the accumulation of
insoluble tau aggregates in the cerebral cortex.
Discussion
Tau pathology is closely correlated with cognitive impair-
ment in Alzheimer’s Disease and is increasingly impli-
Figure 2. cytNmnat1 overexpression does not prevent accumulation of pathologically phosphorylated and misfolded tau in hippocampus of
P301S Tg mice. (A) Representative images showing immunohistochemical analysis of pathogenic tau phosphorylation in the hippocampus of 12-
month female P301S tau Tg and cytNmnat1; P301S double transgenic (DTg) mice using MC1 antibody. Severe tau pathology was observed in
both strains of mice. (B) Quantification of MC1 immunoreactivity in retrosplenial cortex (RS CTX) CA3 region and hilus of the dentate gyrus (DG)
of the hippocampus of wt, cytNmnat1, P301S, and DTg mice shows similar accumulation of misfolded phospho-tau in both P301S and DTg
hippocampi in these two regions. (C) Representative images showing immunohistochemical detection of phospho-tau using AT8 antibody in
P301S and DTg brains. (D) Quantification of AT8 immunoreactivity in the whole anterior hippocampus (HIPP) and retrospenial cortex (CTX) of
both genotypes. N.S: not significant (P > 0.05) by one-way ANOVA with Bonferroni’s posttest. Scale bar = 500 lm.
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cated as a critical mediator of neurodegeneration in a
growing number of diseases.9 Thus, identification of path-
ways which mitigate tau toxicity has tremendous implica-
tions for understanding or treating neurodegenerative
diseases. Nmnat proteins have been well established as
potent protective factors in the setting of axonal injury,
although the specific mechanisms mediating this protec-
tion are still under investigation.1,2,7 Drosophila Nmnat
has been shown to be protective in a fly model of tauopa-
thy,15 whereas viral overexpression of Nmnat1 or Nmnat2
can protect cortical neurons from tau-induced cell death
in rTg4510 Tau transgenic mice.17 However, no previous
studies have evaluated cytNmnat1 in a tau model, or have
they provided detailed immunohistochemical analysis of
the effect of Nmnat overexpression on pathologic forms
of tau. Herein, we present data which suggest that overex-
pression of cytNmnat1 in a mouse model of chronic
tauopathy (human P301S tau transgenic mice) fails to
prevent accumulation of detergent-soluble misfolded and
phosphorylated tau, or downstream inflammation, oxida-
tive stress, and hippocampal atrophy. However, Nmnat1
does preserve cortical functional connectivity, and miti-
gates the accumulation of insoluble tau aggregates in the
brain. These results suggest that optimization of Nmnat1
activity in the brain might help to preserve neuronal
function in the setting of severe tau pathology, such as
that seen in the hippocampus and cortex of Alzheimer’s
disease patients.
Several previous studies have examined the effect of
Nmnat isoforms on tau pathology. In a drosophila model
Figure 3. No effect of cytNmnat1 overexpression on brain atrophy or inflammation in P301S tau Tg mice. (A) Volumetric analysis of anterior
hippocampus in P301S tau and DTg mice. (B) Quantification of sensorimotor cortex thickness in P301S tau and DTg mice. **P < 0.05 by two-way
ANOVA with Bonferroni’s posttest. n.s.: nonsignificant by the same test. (C) qPCR analysis of mRNA levels of Gfap (a marker of astrogliosis) and
Tnfa (an inflammatory cytokine) in all four mouse genotypes. **P < 0.05 by one-way ANOVA as compared to wt. n.s.: nonsignificant.
Figure 4. Reduction in accumulation of insoluble tau aggregates in cerebral cortex by cytNmnat1. Cerebral cortex tissue samples were subjected
to serial extraction in RIPA, RAB, and 70% Formic acid (FA) buffers. Total tau was then quantified in each set of fractions via ELISA. No significant
differences were observed in soluble forms of tau (RIPA and RAB fractions, panels A and B). However, a significant decrease in insoluble,
aggregated tau (70% formic acid fraction) was observed in DTg cortex as compared to P301S cortex. *P < 0.05 by two-tailed T-test.
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of tauopathy, dNmnat overexpression prevented neuronal
vacuolar degeneration and reduced levels of phospho-tau
(including AT8-positive species) in fly heads.15 In this
model, Nmnat appeared to interact directly with patho-
genic tau species and promote their ubiquitin-mediated
degradation by the proteasome. Indeed, dNmnat also sup-
presses neuronal toxicity associated with the toxic protein
SCA2 in drosophila via a proteasome-dependent chaper-
one-like mechanism.27 Studies in yeast suggest that this
chaperone function may be an NAD+-independent prop-
erty of Nmnat.28 A previous mouse experiment showed
an Nmnat2-mediated decrease in phospho-tau and mis-
folded tau in the brains of the r4510 model of tauopathy
by Western blotting with MC1 and CP-13 antibodies.17
We observed no effect of cytoplasmic Nmnat1 on phos-
pho-tau pathology in our study, suggesting that Nmnat1
may not possess the same ability as Nmnat2 to act as a
chaperone to facilitate degradation of phospho-tau. It is
notable that the previous study also examined MC1 levels
in much younger (3.5-month) mice, which could also
contribute to this discrepancy with our findings in a dif-
ferent model (P301S) at a much older age (12 months).
Our observation that Nmnat1 overexpression leads to a
specific decrease in detergent-insoluble tau aggregates sug-
gests that Nmnat1 may somehow target certain insoluble
tau species for degradation, thus leaving the soluble tau
pool unaffected. Thus, it is possible that different Nmnat
isoforms have unique affinities for different tau species,
although this hypothesis has not yet been formally tested.
Although we did not observe any effect of cytNmnat1
overexpression on overall proteasome activity in trans-
fected cells (data not shown), future detailed analysis of
the effect of different Nmnat isoforms on proteolytic
pathways (including autophagy and the proteasome) and
chaperone systems would be valuable.
We also observed no effect of Nmnat1 overexpression
on tau-induced brain atrophy in our study, in contrast to
the only other previous murine study employing AAV-
expressed Nmnat1 or Nmnat2 in the rTg4510 tau
model.17 This may again be due to the different mouse
tauopathy models used in these two experiments, as
rTg4510 mice overexpress human tau with a different
mutation (P301L) and have a more accelerated neurode-
generative course, suggesting that different cytotoxic
mechanisms may be at play. Again, we looked at much
older mice (12 months vs. 4 months) with more severe
disease. Future studies could examine cytNmnat1 overex-
pression or deletion in the rTg4510 mouse tauopathy
model, or examine earlier time points in the disease pro-
gression of P301S mice to address these discrepancies. It
is still unclear to what extent the chaperone activity of
Nmnat isoforms contributes to their relative neuroprotec-
tive effects in vivo. It is possible that the preservation of
function connectivity that we have observed is related to
the ability of Nmnat1 to mitigate the accumulation of
detergent-insoluble tau species, although a more detailed
understanding of the specific tau species which mediate
neuronal dysfunction, as well as the impact of Nmnat1
expression on the accumulation of these specific mole-
cules is needed to formally reach this conclusion.
Several studies have suggested that in addition to their
known effect on axons that Nmnat isoforms can also pre-
vent neuronal cell death caused by toxic protein overex-
pression in flies (polyglutamine-expanded SCA2 or
mutant human tau) or by hypoxic-ischemic injury in
mice.8,15,27 Our data suggest that cytNmnat1 does not
prevent neuronal loss in the P301S chronic tauopathy
model, as no diminution of tau-induced hippocampal or
cortical atrophy was observed. One interpretation of our
data is that although Nmnat1 is unable to prevent patho-
genic tau phosphorylation and subsequent brain atrophy
and inflammation, it may be able to preserve axonal func-
tion in remaining neurons, leading to preservation of
functional connectivity. This would be in keeping with
the known axonoprotective function of cytNmnat1.
Although axonal degeneration is a major pathologic con-
cern in the spinal cord and peripheral nervous system, its
role in chronic neurodegenerative diseases of the brain
has also been described.29 Axonal injury and degeneration
are present in post mortem brains from patients with AD,
and both amyloid-beta and tau-expressing mouse models
of AD exhibit axonal damage which likely contributes to
observed cognitive deficits.30–35 Thus, targeting Nmnat1
in AD and other chronic neurodegenerative diseases of
the CNS could potentially have beneficial effects by pre-
serving axonal function in injured neurons, although
more detailed examination of both the mechanisms of
axonal injury in tau models, as well as of the effect of
Nmnat isoforms on this pathology, is needed in the
future.
In summary, our data demonstrate that cytNmnat1 can
preserve the functional connectivity of cortical neurons
in vivo in the setting of severe tau-mediated neurodegen-
eration without significantly reducing phospho-tau
pathology or brain atrophy. Further investigation into the
mechanisms by which different tau isoforms interact with
various classes of aggregates tau species, as well as devel-
opment of novel methods to optimize Nmnat expression
in the aging brain will help to illuminate Nmnat proteins
as potential therapeutic targets for age-related neurode-
generative diseases.
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Supporting Information
Additional Supporting Information may be found online
in the supporting information tab for this article:
Figure S1. cytNmnat expression is not significantly
impacted by P301S transgene expression. Nmnat1 mRNA
was quantified by qPCR in cortex samples. *P < 0.05 by
one-way ANOVA with Bonferroni’s posttest as compared
to wt.
Figure S2. Inflammation and oxidative stress response in
P301S tau mice are not altered by cytNmnat1 overexpres-
sion. Cortex samples from wt, cytNmnat1, P301S, and
DTg mice were subjected to qPCR analysis of mRNA
expression of Il6 (inflammatory cytokine), Hmox1 and
Pla2g3 (oxidative stress responsive genes), and Hspa1a (a
subunit of the chaperone hsp70). A trend toward increase
in all markers was observed in tau-expressing mice. How-
ever, no significant difference between P301S and DTg
mice was observed for any of these markers. **P < 0.05
by one-way ANOVA as compared to wt. n.s. nonsignifi-
cant.
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